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Abstract
This study was planned to explore the capability of nanoemulsions (NEs) consisting of 
CapryolTM 90 and oleic acid for the delivery of rapamycin (RAP). Permeability and cytotoxicity 
of RAP-loaded NEs were also inspected. Pseudo-ternary phase diagrams were created with 
oleic acid and CapryolTM 90 (as oil phase) and four surfactants and co-surfactants at various 
weight ratios (Rsm). Selected NEs from O/W region on the phase diagrams with the drug 
concentration of 1 mg/mL, were prepared via the spontaneous emulsification technique, 
characterized for particle size and subjected to stability tests at various temperatures over 9-12 
months. Cumulative drug release was determined for a period of 48 h using a dialysis sac. The 
assay of RAP was determined using HPLC technique. Cytotoxicity of NEs was evaluated by 
MTT assay on breast cancer cell line, namely SKBR-3. The permeability of RAP-loaded NEs 
across Caco-2 monolayers was assessed by measurement of TEER (transepithelial electrical 
resistance) value. The intracellular uptake of coumarin 6-loaded NEs by SKBR-3 cells was 
also investigated using florescence microscopy. NEs containing oleic acid/Tween 20/propylene 
glycol, CapryolTM 90/Tween 20/iso-propanol, and CapryolTM 90/Cremophor® RH40/Transcutol® 
P showed more cytotoxicity and permeability compared with the RAP methanolic solution. The 
minimum toxic concentration of RAP in NE formulations was found to be 7.5 µg/mL. The 
highest intracellular uptake was observed for the NE composed of CapryolTM 90/Tween 20/iso-
propanol which was in consistent with the results obtained from cytotoxicity and permeability 
tests. The overall results implicated that this novel carrier was effective for enhancing RAP 
permeation in Caco-2 cell membrane along with enhancement of cytotoxicity.
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Introduction
Rapamycin (RAP), also identified as 
sirolimus, is an antibiotic from macrolide family 
with both immunosuppressant and anti-tumor 
properties. It is extracted from Streptomyces 
hygroscopicus. It works by inhibition of the 
mammalian target of rapamycin (mTOR), as a 
member of protein kinase family. mTOR could 
control several cellular processes, comprising 
of cell growth, cell proliferation, as well as 
transcription and synthesis of protein. Previous 
investigations have pointed to mTOR as an ideal 
target for anti-cancer agents. RAP inhibits tumor 
growth by preventing tumor cell apoptosis, and 
angiogenesis. It suppresses immune actions by 
inhibition of T and B cell proliferation with the 
same mechanisms (1-4).
Despite the promising pharmacological 
activities, at the same time, RAP possesses some 
improper characteristics. RAP is an intensely 
hydrophobic drug and practically insoluble in 
water (2.6 µg/mL). Its sensitivity to gastric acid 
and high hepatic first-pass metabolism results 
in limited intestinal absorption and low oral 
bioavailability, respectively. On the other hand, 
this lipophilic drug is the substrate of CYP450 3A 
enzymes and P-glycoprotein (P-gp) efflux pump, 
present at cell membrane. These characteristics 
have been considered as significant factors that 
contribute to low oral bioavailability (5-13). 
In addition, RAP shows limited distribution to 
the site of action as a consequence of intensely 
partition into the erythrocytes (14). 
Systemic administration of RAP could also 
produce a sum of adverse effects which could 
affect its therapeutic effectiveness. Extensive 
distribution in many organs, a very long half-life 
and a strong immunosuppressive effect following 
the systemic administration limit the long-term 
clinical application of RAP (15). RAP poor 
solubility in some common parenteral solvents 
(e.g., ethanol, propylene glycol, propylene 
glycol) and the lack of any functional group with 
the ability to ionize in the pH range of 1-10, have 
consequently made the preparation of injectable 
formulations difficult (11, 16 and 17).
There are various methods available to 
formulate poorly water soluble drugs. Many 
investigations have been conducted to develop 
new delivery systems for RAP, mainly in an 
attempt to increase the solubility and dissolution 
properties, to improve bioavailability and 
loading of drug, to increase the drug protection 
and stability, and to provide drug targeting and 
extended release pattern. Some examples are 
the use of poly(lactic-co-glycolic)acid (PLGA) 
microparticles (18, 19), poly(l-lactide-co-
caprolactone-co-glycolide) (PLCG) nanofibers 
(20), chitosan/polylactic acid nanoparticles (21), 
liposomes (16), amphiphilic co-polymer micelles 
of poly(ethylene glycol)-b-poly(epsilon-
caprolactone) (PEG-PCL) (17) and the 
application of solid dispersion and complexation 
techniques with different hydrophilic excipients 
(22). 
Nanoemulsion (NE) is a kind of lipid-
based formulation that has been the focus of 
much research due to its potential advantages 
from the pharmaceutical viewpoint. This self-
emulsifying system is considered as a desirable 
carrier for improving the bioavailability of drugs 
with low water-solubility. Generally accepted, 
NEs are dispersions of oil and water with 
transparent or translucent appearance, stabilized 
by an interfacial layer composed of combined 
surfactant and co-surfactant molecules, with 
droplet size in the range of 50-200 nm. It has 
been reported in the literature that drug delivery 
by NEs is advantageous for some reasons; a) they 
have ultralow interfacial tensions and possess a 
relatively high kinetic stability, with no apparent 
droplet flocculation and coalescence (23, 24) 
(therefore, they are sometimes described as 
“Approaching Thermodynamic Stability”) (25); 
b) the large interfacial areas associated with the 
presence of nano-droplets would affect the drug 
transport property (26); c) high solubilization 
capacity compared to simple micellar solutions; 
d) their long term physical stability offers 
advantages over unstable dispersions; e) they are 
easily prepared; f) they improve the solubility 
and the mucosal permeability of lipophilic 
compounds (27, 28); and g) they protect the 
sensitive drugs from hydrolysis and enzymatic 
degradations in physiologic environments (29-
32). 
The main aim of this study was to attain 
an effective delivery system for RAP. It was 
hypothesized that by loading RAP in NEs, its 
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bioavailability and anti-proliferative effect would 
increase. In the previous study, we developed 
and assessed the toxicity of triacetin-mediated 
NEs (33). The present investigation was planned 
to formulate and characterize CapryolTM 90 and 
oleic acid-based NEs. CapryolTM 90 and oleic 
acids were chosen as the oil phase for the drug 
solubilization. Finally, NEs permeability across 
Caco-2 cell monolayer and their cytotoxicity on 
SKBR-3 cell line were also evaluated. 
Experimental
Materials
Tween 80, Tween 20, triacetin, iso-propanol, 
polyethylene glycol 400 (PEG 400), propylene 
glycol (PG) and methanol were purchased from 
Merck Chemical Co. (Germany). Labrasol 
(caprylocaproyl macrogol-8-glycerides) and 
Transcutol® P (diethylene glycol monoethyl 
ether) were gifted by Gattefosse Co. (France). 
Cremophor RH 40 was provided as a gift 
from Osvah Pharmaceutical Co. (Tehran, 
Iran). Penicillin-streptomycin (Pen strep) 
100X and RPMI 1640 medium were provided 
from Biosera (England). Dulbecco’s Modified 
Eagle’s Medium (DMEM-high glucose), fetal 
bovine serum (FBS), trypsin-ethylenediamine 
tetraacetic acid (EDTA), 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) 
and Hank’s Balanced Salt Solution (HBSS) 
were prepared from PAA Laboratories GmbH 
(Austria). Trypan blue (0.4% w/v in PBS) and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) were provided 
from Sigma (USA) and DMEM F12 was 
obtained from Atocel (Austria). Purified water 
was collected from a Millipore Milli-Q plus 
Water Purification System (Millipore, France). 
Rapamycin (RAP; sirolimus, batch number 
SIRI0012) and Rapamune were purchased from 
Euticals Spa Co. (Italy), and Pfizer (Netherlands), 
respectively.
Construction of pseudoternary phase 
diagrams 
Mixtures of surfactants (Tween 20, Tween 
80, Labrasol® and Cremophor® RH 40) and co-
surfactants (Transcutol P, iso-propanol, PEG and 
PG) at different surfactant/co-surfactant weight 
ratios (Rsm; namely, 1:2, 1:1, 2:1) were prepared. 
Appropriate amounts of oleic acid or CapryolTM 
90 were mixed with the appropriate amounts of 
the surfactant mixture phase, in order to prepare 
oil-surfactant mixtures with three weight ratios 
(1:9 to 9:1). The samples were mixed in capped 
vials at room temperature till a transparent 
solution was prepared. For construction of phase 
diagrams, the samples were titrated with distilled 
water and agitated for a necessarily long time to 
attain the equilibrium. Each titration was checked 
both visually and through cross-polaroids for 
determining the clarity and birefringent liquid 
crystalline phase, respectively. Triangle phase 
diagrams were plotted with the three apices 
demonstrating a fixed Rsm, oil and water contents. 
All mixtures, produced optically transparent or 
translucent, non-birefringent, isotropic solutions 
at low oil and low water domains were termed 
oil in water (o/w) and water in oil (w/o) NEs, 
respectively.
High performance liquid chromatography
The samples were assayed by a previously 
described HPLC method (34). HPLC analysis 
was implemented on Knauer HPLC system 
(Germany), comprising of a UV detector 
(Smartline 2500), pump (Smartline 1000), and 
software (Chromgate V3.1.7). Separation was 
done by using a reversed phase C8 column 
(MZ, 15 × 4.6 mm, 5 μm, MZ Analysentechnik 
GmbH, Germany). A suitable guard column 
was also used. A combination of methanol : 
water (80:20 v/v) was used as mobile phase 
that freshly prepared and degassed every day. 
Column temperature was fixed at 57 °C (Knauer, 
Germany). The injection of samples was 
performed on a Reodyne injector equipped with 
a 20 μL loop. UV detector was set at 277 nm. 
The method was confirmed for RAP assay with 
respect to specificity, linearity, precision (intra/
inter-day RSD), and accuracy.
Determination of rapamycin solubility in 
oleic acid and CapryolTM 90 
The solubility of RAP in oleic acid and 
CapryolTM 90 was assessed by addition of excess 
quantity of the drug in 1 mL of the each oil. The 
mixture was agitated at room temperature for 72 
h to be equilibrated. The excess of the drug was 
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removed and the sample was centrifuged for 15 
min at 14000 rpm. The supernatant was filtered 
through 0.2 µm membrane filter. The solubility 
of RAP was then estimated by the above-
mentioned HPLC method.
Preparation of nanoemulsions containing 
rapamycin
The type of components and their required 
concentrations which lead to the production 
of NEs were determined by construction of 
pseudo-ternary phase diagrams. Following 
the determination of o/w NE regions on the 
phase diagrams, those systems that indicated 
a relatively extended o/w NE domain and that 
allowed to choose an oil content for complete 
solubilization of the drug, were selected. 
Following the preparation of the selected blank 
NEs and measurement of their particle size, 
those systems with the particle size of less than 
100 nm and polydispersity index (PDI) of less 
than 0.5 which remained transparent/translucent 
after 72 h storage at room temperature, were 
chosen for drug loading.
RAP-NEs were prepared using spontaneous 
emulsification technique. One mg of RAP 
was added to 1 mL of mixture containing oil/
surfactant/co-surfactant with constant stirring, 
using a mechanical stirrer, until a transparent 
solution was obtained. Finally, the required 
amount of water was added and the mixture was 
agitated gently until a transparent/translucent 
NE was achieved.
Measurement of particle size and zeta 
potential 
The size of particles, PDI, and zeta potential 
of all NEs containing RAP were measured, 
using Malvern Zetasizer (Nano-ZS, Malvern 
Instruments, Worcestershire, UK), with Nano-
ZS software for data analysis. All analyses were 
implemented three 3 times.
Transmission electron microscopy (TEM)
To observe the two-dimensional, relative 
size morphology of RAP-loaded NE particles, 
a drop of the sample was directly deposited 
on the holey film grid and after drying, the 
images were taken with magnification of 11000, 
using a transmission electron microscope 
(Philips CM30, Netherlands).
In-vitro drug release 
The profile of RAP release from the 
developed NEs was assessed by the dialysis bag 
method. Dialysis bags (MWCO 12 KD, Iran) 
were placed in distilled water for 24 h and kept 
refrigerated until usage. One mL of the drug-
loaded NE (containing 1 mg RAP) was packed 
in a dialysis bag, which was then sealed with 
clips at both ends and placed in release medium 
(100 mL water having 0.05% w/v Tween 80). 
The assembly was stirred with speed of 100 rpm 
at 37 ± 1 °C and the aliquots of 2 mL were taken 
from the dissolution media at predetermined 
certain times (1, 2, 4, 8, 12, 24, 36 and 48 h). The 
same volume of fresh media was added to ensure 
the sink condition. The samples were evaluated 
for drug content using an HPLC method as 
described above.
Stability tests
Developed RAP-loaded NEs were subjected 
to stability test. The samples were stored at 4, 25, 
and 40 °C and also, their stability was checked 
over a period of 9-12 months. Phase separation, 
particle size, PDI, and drug content of NEs were 
then assessed.
Cell culture
Live SKBR-3 cells (National Cell Bank of 
Iran Code: 207) were purchased from Pasteur 
Institute of Iran (passage number: 8). The cells 
were cultured in 25 cm2 plastic flasks (Nunc, 
Denmark) in an enriched media containing 
84% v/v Dulbecco′s Modified Eagle’s Medium 
(DMEM high glucose), 15% v/v FBS and 1% 
v/v penicillin-streptomycin-100x (pen-strep) and 
incubated in a controlled moistened incubator 
having 5% CO
2
 and 95% air at 37 °C. The 
culture medium of flask was altered every two 
days. To passage the cells after reaching to 70-
80% cell consistency, the cells were trypsinized 
with trypsin-EDTA (1x) and resuspended in the 
culture medium and kept at 37 °C. The cells 
with passage number up to 20 were used for 
cytotoxicity study.
For permeability study, Caco-2 cell line 
(passage number 40-50) was used. The cells were 
incubated at 37 °C in 75 cm2 plastic flasks in a 
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controlled moistened atmosphere of 5% CO
2
 and 
95% air, using 15 mL of a medium containing 
50% v/v RPMI 1640, 34% v/v DMEM F12,15% 
v/v FBS and 1% v/v penicillin-streptomycin 
(100 IU/mL). Culture medium was replaced 
every two days. At final stage, the cells were 
trypsinized with trypsin-EDTA (1x), passaged 
and maintained for 7 days to reach the 80-90% 
confluency. The cells with a passage number up 
to 20 were used for cytotoxicity studies.
Cytotoxicity assay
Cytotoxicity of drug-free and drug-loaded 
NEs was evaluated, using MTT to assess the 
viability of cells (35). The cells at the density 
of 1 × 104 viable SKBR-3 cells per well were 
cultured in 96-well microplate and incubated 
for 48 h to allow the cell attachment. The cells 
were incubated with blank NEs, RAP-loaded 
NEs, and RAP-methanolic solution with the 
final drug concentrations of 7.5, 10, and 15 nM, 
respectively, in an atmosphere of 5% CO
2
 at 37 
°C for 48 h. For each concentration, three wells 
were used per plate. Two wells were allocated 
for negative (treated with medium only) and 
positive (treated with DMSO) controls. After 
washing with PBS, the cells remained in 
contact with 20 µL of MTT solution (5 mg/
mL) at 37 °C. Following 4 h incubation, 100 
µL of DMSO was then added to each well, 
while stirring vigorously, in order to dissolve 
formazon crystals. The optical absorbance of 
each well was measured using enzyme-linked 
immunosorbent assay reader (Anthous 2020; 
Anthos Labtec Instruments, Salzburg, Austria) 
at the wavelength of 550 nm. The cell viability 
was finally determined as a percentage of the 
negative control.
Measurement of Transepithelial Electrical 
Resistance (TEER)
Semipermeable polycarbonate filter inserts 
(Nunc 12-well transwell plates, pore size 0.4 µm, 
surface area 13 cm2) were used to seed Caco-2 
cells. The filters were precoated with 100 µL of 
diluted rat tail collagen (type Ι) solution (in 0.1 
N acetic acid with the ratio of 1:9) in an attempt 
to enhance the cell adhesion. Coated filter inserts 
were incubated overnight to become dried. The 
cells with density of 4 × 105 cells/cm2 were 
then seeded on polycarbonate filters (36, 37). 
Transepithelial electrical resistance (TEER) of 
Caco-2 cell monolayer was measured for 21 days 
after seeding the cells on the filter to estimate 
the monolayer integrity. EVOM 2 voltohmmeter 
with chopstick electrodes (World Precision 
Instruments, Sarasota, USA) was employed for 
TEER measurement. Culture medium at both 
apical (500 µL) and basolateral sides (1500 
µL) was changed every other day. Mean TEER 
values across the Caco-2 cell monolayers were 
measured with the formula below: 
TEER = (Rmonolayer - Rblank) × A (Ω.cm
2)
where Rmonolayer indicates the resistance of Caco-
2 monolayer, A is the available surface area of 
the filter inserts and R
blank 
shows the resistance of 
inserts without Caco-2 monolayer. TEER values 
between 200-400 Ω.cm2 show a good integrity of 
the cell monolayer. TEER evaluation were also 
performed during the permeation study at the 
specific times (0, 1, 2, 3, 4, 8 and 24 h) after the 
permeation tests in order to assess the effects of 
NEs on opening the tight junction barriers. 
Transport study
To conduct the transport tests, the cells 
were washed twice with PBS and incubated 
with transition buffer comprising HPSS (pH 
7.4) supplemented with 25 mM HEPES for 30 
min. After removing the transition buffer, RAP-
loaded NEs and RAP methanolic solution were 
placed in the apical side of cell monolayer at the 
concentration of 1 mg/mL. Transition buffer (1.5 
mL) was placed in the basolateral side of the 
monolayer. All transport analysis was performed 
at 37 °C from apical (A) to basolateral (B) 
direction of cell monolayer. The samples 
were taken at predetermined time intervals (0, 
1, 2, 3 and 4 h) from the basolateral side and 
analyzed with HPLC method described above. 
The apparent permeability coefficient (Papp) 
was finally calculated according to the formula 
below: 
Papp = Q/(A × t × C0)
where Q is the cumulative amount of the drug 
in the receptor compartment, A represents the 
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surface area of filter, t is the time of sampling 
and C0 indicates the primary drug concentration 
in the apical compartment.
Cellular uptake of nanoemulsions
In a 12-well plate, SKBR-3 cells were 
cultured with density of 40000 cells per well 
and incubated in the presence of NEs loaded 
with coumarin 6 and also methanolic solution of 
coumarin 6 (as the control) at a concentration of 
0.5 µg/mL. After 6 h, the cells were washed with 
PBS and the cellular uptake of coumarin 6-loaded 
NEs was then evaluated using fluorescence 
microscopy. The intensity of fluorescent color in 
each obtained image was finally determined.
Statistical analysis
Data are reported as mean ± SD. Statistical 
study of differences between the samples was 
carried out using one-way ANOVA and an 
appropriate post-test, if necessary. The level of 
probability, 0.05, was considered as the level of 
significance.
Results and Discussion
Phase behavior studies
Phase diagrams of systems comprising of two 
different oils (oleic acid and CapryolTM 90), four 
different surfactants and co-surfactants at three 
Rsm were constructed. Due to the small o/w NE 
area in the presence of oleic acid and because 
of the similarities between the phase diagrams 
constructed with CapryolTM 90, in order to avoid 
overcrowding of the report, only the phase 
diagrams of systems composed of CapryolTM 
90/Tween 20 are presented diagramatically. 
Wherever appropriate, any differences between 
phase behaviors observed with other surfactants 
are mentioned in the text. Figures 1-4 illustrate 
the diagrams of CapryolTM 90/Tween 20 mixtures 
in the presence of all co-surfactants.
As can be seen, a mixture of CapryolTM 90/
Tween 20 can produce three different transparent 
areas, including a transparent/translucent domain 
in the water-rich region, a transparent domain in 
the oil-rich part and a surfactant–rich (SR) area, 
designated as o/w, w/o, and SRA, respectively 
(except for Tween 20/PEG 400/water at Rsm 
of 1:2), the extent of which depended upon 
the nature of co-surfactant and Rsm. It should 
be noted that since accurate determination 
of the boundaries between the NE domains 
and SR region was difficult, the area with the 
extension up to 50% w/w surfactant mixture 
was considered as NE, above which the area was 
labeled as SR domain. Despite some differences 
between the phase diagrams, it is advantageous 
to mention the similarities. Generally, the 
following generalizations can be made about the 
systems studied:
CapryolTM 90 systems
• In most systems, regardless of the type of 
surfactant and co-surfactant, the change 
of Rsm did not affect the extent of NE area 
significantly.
• Except for Labrasol®/iso-propanol and 
Tween 80/iso-propanol systems, all three 
o/w, w/o and SR domains were observed,
• The extent of NE domain in the presence 
of co-surfactants followed the order of iso-
propanol > Transcutol®  P > PG > PEG 400.
• Transparent o/w NE formulations were 
generally prepared with low viscosity. 
However, few systems were translucent 
especially at high water content. 
• The extent of NE increased as the amount of 
surfactant mixture increased.
• The largest o/w NE area was seen in 
the presence of Cremophor® RH40 and 
Transcutol® P, whereas the smallest domain 
was observed in the presence of Labrasol® 
and PG.
• No NE area was detected in formulations 
composed of Labrasol®, PEG 400 and 
CapryolTM 90.
• No liquid crystal phase was observed in all 
formulations.
• None of the systems with less than 10 
wt% total surfactant concentrations could 
solubilize water. 
Oleic acid systems
• In most formulations, depending upon the 
type of the co-surfactant and Rsm, w/o NE 
region with various extents was observed.
• No o/w NE can be produced in the presence 
of PEG 400 as the co-surfactant.
• Water and oil solubilizing capacities 
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increased with increasing surfactant/co-
surfactant content, irrespective of the Rsm. 
• By using PG as the co-surfactant, a very 
narrow o/w NE region was observed in a 
few systems, such as Labrasol®/PG (Rsm of 
2:1) and Tween 20/PG (Rsm of 1:2).
• Regardless of type of surfactant, iso-
propanol seemed to be the most appropriate 
co-surfactant for producing o/w NEs.
• In most formulations, a change of Rsm could 
affect the phase behavior.
• No liquid crystal phase was observed in all 
formulations.
• O/w NE formulations generally appeared to 
be transparent with low viscosity. However, 
systems composed of Tween 20, Tween 80, 
Labrasol and Cremophor® RH 40 in the 
presence of iso-propanol at Rsm of 1:1 and 
1:2 were translucent at high water content.
• None of systems with less than 10 wt% total 
surfactant concentrations could solubilize 
water.
Selection of o/w nanoemulsions from phase 
diagrams
Based on the extent of o/w region on the 
constructed phase diagrams, o/w NEs were 
selected for drug incorporation, considering 
the minimum possible surfactant/co-surfactant 
concentration, allowing the access to the enough 
oil content for complete solubilization of RAP 
and achievement of stable RAP-loaded NEs 
without any drug precipitation. Among 48 
systems containing oleic acid and 48 systems 
Figure 1. Phase diagrams of quaternary systems containing CapryolTM 90/Tween 20: Transcutol® P/water at (A) Rsm of 1:1; (B) Rsm of 
1:2; and (C) Rsm of 2:1 (O/w, w/o and SR represent oil-in-water, water-in-oil and surfactant-rich areas, respectively).
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Figure 2. Phase diagrams of quaternary systems containing CapryolTM 90/Tween 20: iso-propanol/water at (A) Rsm of 1:1; (B) Rsm of 1:2; 
and (C) Rsm of 2:1 (O/w, w/o and SR represent oil-in-water, water-in-oil and surfactant-rich areas, respectively).
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composed of CapryolTM 90, only 10 and 13 
formulations showed the desired features, 
respectively, and therefore they were selected 
for characterization studies concerning the 
particle size and clarity. Finally, those systems 
with particle size of less than 100 nm, PDI of 
less than 0.5 which were clear after 72 h were 
selected for drug loading (1 mg RAP/mL of NE) 
and further investigations. Table 1 presents the 
components of all blank NEs chosen from the 
phase diagrams and indicates those systems that 
were used for drug incorporation, at a fixed total 
surfactant concentration of 40% w/w.
Pharmaceutical acceptability and safety of 
components are the most important criteria which 
should be considered in the formulation of NEs 
with appropriate characteristics. Appropriate 
mixture of oil, surfactant, and co-surfactant 
could result in a wide and efficient NE area (38). 
Surfactants are adsorbed at water/oil 
interface, resulting in a reduction in the 
interfacial tension to a very small value and could 
produce a film around the droplets with a proper 
curvature at the interface (41, 42). However, 
for the formation of a NE, a single surfactant is 
rarely able to provide a low interfacial tension 
and therefore, the addition of a co-surfactant 
is usually necessary. It has been reported in 
the literature that without a co-surfactant, an 
extremely inflexible surfactant film may form, 
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leading to the production of nanoemulsions in 
very limited range of component concentrations 
(41, 42). Therefore, co-surfactant molecules 
(such alcohols with short and medium chain 
length) are frequently used to further decrease 
the interfacial tension, increase the fluidity of the 
interfacial film allowing various curvatures (43-
47), reduce the bending stress of the boundary 
surface causing spontaneity of emulsification, 
lowering of size and polydispersity of droplets 
(44, 48).
The weight ratio of surfactant/co-surfactant 
has also been reported to have an important 
impact on size distribution, position, and the 
extent of NE area (42, 49, and 50). In this 
investigation, Rsm of 1:1, 1:2, and 2:1 was 
selected to evaluate the effect of increasing/
decreasing concentrations of surfactants and co-
surfactants.
Solubility
Drug solubility in oil phase is a main 
prerequisite for the production of a stable 
NE formulation (26, 43). As a result of low 
solubility, many formulations would face with 
precipitation before in-situ solubilization (39). 
For the production of a stable NE formulation, 
solubility of drug in oily component is 
usually needed to be determined. The higher 
drug solubility in oil phase, the less need for 
Figure 3. Phase diagrams of quaternary systems containing CapryolTM 90/Tween 20/ PG/ water at (A) Rsm of 1:1; (B) Rsm of 1:2; and 
(C) Rsm of 2:1 (O/w, w/o and SR represent oil-in-water, water-in-oil and surfactant-rich areas, respectively).
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incorporation of surfactants and co-surfactants 
(51, 52). Solubility measurement showed that 
RAP’s solubility in CapryolTM 90 and oleic acid 
was 3.14 ± 0.02 mg/mL and 37.53 ± 0.23 mg/
mL, respectively, which denote the potential of 
these oils for RAP solubility.
Particle size and polydispersity index 
Average particle size and size distribution 
of RAP-loaded NEs were evaluated by 
dynamic light scattering technique. PDI was 
also determined to provide information about 
the deviation from the mean size. PDI is a 
measure of droplet size uniformity. The higher 
the polydispersity, the lower the uniformity 
of the particle size in the formulation. Table 2 
represents the results of size and PDI analysis. 
As can be seen, nearly in all systems, the 
average size of the NE droplets was less than 
100 nm. Formulation F78 containing oleic acid/
Cremophor® RH 40/Transcutol® P at the Rsm of 
2:1 yielded a nanoparticle diameter of 26.85 nm 
with a PDI of 0.584, whereas F124 containing 
CapryolTM 90/Cremophor RH40/Transcutol® P at 
the Rsm of 1:1 showed a nanoparticle diameter of 
100.28 with a PDI of 0.482.
Although small differences were observed, 
however, all of the formulations investigated 
were composed of nano range droplets (≤100 
nm). PDI is a measure of droplet size uniformity 
Figure 4. Phase diagrams of quaternary systems containing CapryolTM 90/Tween 20/PEG 400/water at (A) Rsm of 1:1; (B) Rsm of 1:2; and 
(C) Rsm of 2:1 (O/w, w/o and SR represent oil-in-water, water-in-oil and surfactant-rich areas, respectively).
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in the formulation. As can be seen in Table 2, 
most NEs selected for the in-vitro release study, 
showed PDI values less than 0.5, with the 
minimum value of 0.256 (in case of F98). 
In-vitro release studies
In this investigation, dissolution studies were 
carried out to compare the RAP release pattern 
from the NEs and confirm the release of the drug 
in an adequate manner. As mentioned earlier, the 
release behavior was studied in water having 
0.05 % w/v of Tween 80 at 37 °C and the release 
percentage of the drug was plotted vs time up 
to 48 h. The release patterns of RAP from the 
NEs listed in Table 2 are shown in Figures 5 
and 6 and the corresponding data obtained after 
48 h are presented in Table 3. As illustrated 
from the plots for oleic acid-based NEs, except 
for F87, the profiles generally exhibited a 
relatively constant slow RAP release within 48 
h, presenting a typical sustained drug release. 
None of the formulations exhibited complete 
drug release after 48 h; however, the change of 
release rate was found to be dependent upon the 
components existing in NEs. The highest and 
lowest releases were observed for F87 and F78 
Table 1. Composition of blank nanoemulsions, prepared at fixed total surfactant concentration of 40% w/w, selected for RAP loading.
Formulation Component Rsm Oil (wt%) Water (wt%) Result*
F50 OA/T20/iso-prop 1:2 10.07 49.93 √
F51 OA/T80/iso-prop 2:1 14.82 45.18 -
F56 OA/T20/PG 1:2 10.24 49.76 √
F64 OA/T80/Tr 1:1 8.98 51.02 -
F74 OA/Crem/iso-prop 1:2 10.00 50.00 √
F75 OA/Crem/iso-prop 2:1 8.16 51.80 -
F78 OA/Crem/Tr 2:1 8.58 51.42 √
F87 OA/Lab/iso-prop 2:1 8.58 51.42 √
F90 OA/Lab/Tr 2:1 8.58 51.42 √
F97 Cap/T20/iso-prop 1:1 15.24 44.76 √
F98 Cap/T20/iso-prop 1:2 9.40 50.60 √
F99 Cap/T20/iso-prop 2:1 8.98 51.02 √
F100 Cap/T20/Tr 1:1 21.90 38.10 -
F105 Cap/T80/PG 2:1 15.66 44.34 -
F111 Cap/T80/iso-prop 2:1 15.24 44.76 -
F112 Cap/T80/Tr 1:1 14.82 45.18 √
F121 Cap/Crem/iso-prop 1:1 15.66 44.34 -
F122 Cap/Crem/iso-prop 1:2 2.14 57.86 -
F123 Cap/Crem/iso-prop 2:1 2.16 57.84 -
F124 Cap/Crem/Tr 1:1 6.90 53.10 √
F125 Cap/Crem/Tr 1:2 1.90 58.10 √
F126 Cap/Crem/Tr 2:1 1.90 58.10 -
T20: Tween 20; T80: Tween 80; Lab: Labrasol®; Crem: Cremophor RH40; iso-prop: iso-propanol; Tr: Transcutol® P; PG: propylene 
glycol; OA: oleic acid; Cap: CapryolTM 90.
*Selected for drug loading.
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formulations, respectively. Statistical analysis 
revealed no significant difference in the release 
profile of F74, F78, and F90 (p > 0.05) as 
compared with marketed product, Rapamune®, 
with 1.2 and 2.1% drug release within 24 and 48 
h, respectively. It should be noted that the release 
from Rapamune® was observed to be incomplete 
which may be attributed to the gradually 
developing opacity of the medium, probably due 
to the precipitation of the drug. 
Plots in Figure 6 depict the release profiles 
from NEs, when oleic acid was replaced by 
CapryolTM 90. F125 and F124 provided the 
highest and lowest drug release respectively. 
Table 2. Droplet size and PDI values of RAP-loaded nanoemulsions (n = 3).
Formulation Z-Average (nm) PDI
F50 39.53 0.378
F56 64.36 0.449
F74 90.39 0.491
F78 26.85 0.584
F87 53.24 0.296
F90 47.49 0.349
F97 72.61 0.342
F98 74.86 0.256
F99 59.69 0.453
F112 77.25 0.483
F124 100.28 0.482
F125 100.2 0.284
Figure 5. In-vitro release profiles of RAP-loaded nanoemulsions in the presence of oleic acid in water containing 0.05% w/v Tween 80 
at 37 °C (n = 3).
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Figure 6. In-vitro release profiles of RAP-loaded nanoemulsions in the presence of CapryolTM 90, in water containing 0.05% w/v Tween 
80 at 37 °C (n = 3).
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Generally, the release of RAP from NEs was found to be slightly higher when compared to Rapamune. 
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and polydispersity, viscosity and drug solubility in the internal oil phase. The enormous interfacial region 
formed by the presence of nanosized droplets could improve the solubility of a poorly soluble drug, as well 
as permitting faster drug release rate, and would consequently have an impact on the transport of the drug 
(26, 29, 39, and 53).  
In this study it was observed that RAP was generally released from NEs very slowly. No burst effect was 
seen and the percentage of drug release was less than 10% (except in one case). Drugs with lipophilic 
character, like RAP, are preferably solubilized in the oil phase of o/w NEs. The capability of maintaining 
these drugs in the solubilized form provides a reservoir for their sustained release. The prolonged in-vitro 
release of the drug observed could be explained by considering the partitioning of the drug towards the oil 
Although a slow sustained release was observed, 
the incorporation of CapryolTM 90 did not 
considerably alter the release profile of the drug 
from NEs. After 24 h, less than 5% of the drug 
was released, followed by a gradual increase 
up to 48 h. Statistically, significant differences 
were observed between RAP release from all 
formulations and Rapamune® after 24 and 48 h.
Generally, the release of RAP from NEs 
was found to be slightly higher when compared 
to Rapamune®. Several key factors should be 
considered regarding the drug delivery potential 
of NEs, including dropl t size and poly ispersity, 
viscosity and drug solubility in the internal oil 
Table 3. Mean cumulative percent of RAP released from nanoemulsions after 48 h (Mean ± SD; n = 3).
Formulation Cumulative release (%)
F50 6.0 ± 0.22
F56 8 ± 1.47
F74 4.4 ±0.15
F78 3.6 ± 0.07
F87 21.5 ± 1.26
F90 4.3 ± 1.21
F97 6.3 ± 0.36
F98 7.0 ± 0.19
F99 6.7 ± 0.15
F112 5.4 ± 0.13
F124 4.3 ± 0.06
F125 7.1 ± 0.07
Rapamycin-loaded nanoemulsions
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Table 4. Results of droplet size, PDI and drug content analysis of nanoemulsions, stored at various temperatures at the end of 9 and 12 
months.
Formulation
4 °C 25 °C 40 °C Drug content (%)
Size (nm) PDI Size (nm) PDI Size (nm) 4 °C* 25 °C**
F56 44.4 ± 0.8 0.223 39.7 ± 0.68 0.360 phase separation 80.8 ± 0.44 4.47 ± 2.41
F87 41.9 ± 1.25 0.376 48.1 ± 1.15 0.203 phase separation 75.5 ± 2.67 6.94 ± 0.03
F98 45.3 ± 0.55 0.291 45.3 ± 0.26 0.233 79.2 ± 3.87 88.5 ± 0.24 52.94 ± 0.11
F125 101.2 ± 4.55 0.354 96.5 ± 1.36 0.269 137.8 ± 2.36 77.2 ± 0.61 57.54 ± 0.18
*9-month storage, **12-month storage.
phase. The enormous interfacial region formed 
by the presence of nanosized droplets could 
improve the solubility of a poorly soluble drug, 
as well as permitting faster drug release rate, 
and would consequently have an impact on the 
transport of the drug (26, 29, 39, and 53). 
In this study it was observed that RAP was 
generally released from NEs very slowly. No 
burst effect was seen and the percentage of drug 
release was less than 10% (except in one case). 
Drugs with lipophilic character, like RAP, are 
preferably solubilized in the oil phase of o/w 
NEs. The capability of maintaining these drugs 
in the solubilized form provides a reservoir for 
their sustained release. The prolonged in-vitro 
release of the drug observed could be explained 
by considering the partitioning of the drug 
towards the oil and this fact that its distribution 
through the oil core and interface is influenced 
through the aqueous media. Rouf and his co-
workers developed and characterized a liposomal 
system for delivery of RAP and evaluated its 
anti-proliferative effect on MCF-7 cells as the 
breast cancer cell line. They observed that the 
percentage of drug release was very slow, with 
no burst effect, and in the vicinity of 10% after 
24 h. They suggested that the drug molecules be 
located in the bilayer, not on the surface of the 
liposomes, as expected for a lipophilic drug (16).
Zeta potential determination
Zeta potential of F56, F87, F98, and F125 
formulations were measured and found to be 
-0.03 ± 0.01, 1.28 ± 0.036, 1.01 ± 0.07, and 
0.09 ± 0.007 mV respectively. Zeta potential, 
as a measure of charge interactions between the 
particles, can affect the stability of NE droplets. 
It has been reported that as the electrostatic 
repulsive forces increase, the possibility of the 
coalescence decreases (53, 54). The greater 
positive or negative zeta potential (net charge 
of droplets), leads to greater stability of the 
dispersion. 
Stability tests 
In contrast to macroemulsions that are 
kinetically stable and show eventually phase 
separation, NEs are considered as systems 
with high thermodynamic stability, with no 
coalescence and phase separation. The selected 
NEs in this research were subjected to thermal 
stability and their drug content, size of droplet 
and PDI were monitored after storage at 4, 25, 
and 40 °C for 9 months. The results are shown in 
Table 4. At 25 °C, a decrease in the particle size 
was observed which might be related to good 
particle stabilization. The same trend was seen for 
the systems stored at 4 °C. At these temperatures, 
no significant change of the PDI value, phase 
separation and turbidity was observed up to 9 
months. In general, the stability results revealed 
that the NEs remained homogenous without any 
sign of instability throughout the tests. At 40 °C, 
only F98 and F125 systems passed the stability 
tests, which was also associated with an increase 
in the size of droplet and PDI values. In terms 
of the RAP assay in NEs, analysis revealed that 
all formulations were capable of solubilizing at 
least 75% of RAP at 4 °C at the end of 9 months, 
whereas the decline in the content of RAP 
after 12 months was more than 90% and 40% 
in oleic acid and CapryolTM 90-mediated NEs, 
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respectively.
Cytotoxicity assay
The cytotoxic effect of RAP-free NEs was 
evaluated by MTT test on SKBR-3 cell line to 
eliminate the possible toxic properties of the blank 
formulations. Cell viability in each formulation 
was expressed as the percentage of negative 
control cells. The results depicted that the blank 
F87 was completely toxic for the cells, even after 
ten times dilution and therefore, this formulation 
was not used for further investigation. In case of 
other formulations, IC
50
 was found to be more 
than the maximum concentration investigated. 
The IC
50
 value of RAP methanolic solution 
was also found to be 50 µg/mL and at lower 
concentration, more than 90% of cell viability 
was observed (33). Figure 7 illustrates the results 
of MTT test on RAP-loaded NEs. Wide range of 
cell death was detected, from 20% for F56 (at the 
concentrations of 7.5 and 10 mcg/mL) to 90 % 
for F98 and F125 (at the concentrations of 10 and 
15 mcg/mL), which was significantly different 
from the results obtained for RAP solution as the 
control (p < 0.001).
In general, the obtained data confirmed that 
the anticancer activity of RAP would change 
by incorporation into NEs. Comparison of the 
results revealed a higher cell death when oleic 
acid in F56 was replaced by CapryolTM 90 (in F98 
and F125), probably due to enhanced penetration 
of RAP-loaded NE droplets to the cells and/or 
more RAP solubilization in CapryolTM 90. Kang 
et al. have studied the solubility of celecoxib 
(a lipophilic drug with anticancer effect) in 
various oils, namely tributyrin, LabrafacTM 
and soybean oil, and developed NE systems. 
Their investigation on human HCT 116 colon 
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Figure 7. Cytotoxic effect of nanoemulsions containing rapamycin on SKBR-3 cell line measured by MTT test (48 h). 15 mcg/mL = 600 
µL NE/400 µL cell culture medium; 1  mcg/mL = 40  µL NE/600 µL cell culture medium; 7.5 mcg/mL = 75  µL NE/250 µL cell culture 
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Table 5. Apparent permeability coefficients of rapamycin-loaded nanoemulsions and methanolic solution.
Formulation Papp (× 10-6 cm/sec) ± SD
F56 3.6 ± 0.36
F98 5.8 ± 0.35
F125 4.2 ± 0.45
RAP methanolic solution 0.9 ± 0.09
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cancer cells have demonstrated that the cellular 
proliferation could be inhibited more effectively 
by combined treatment with free drug and 
tributyrin emulsions. Therefore, they suggested 
that the enhanced anticancer effect of celecoxib 
by using tributyrin emulsions was possibly due to 
the higher capacity of solubilization (compared 
to the other oils), as well as the anticancer 
activity of tributyrin emulsion (55). Although 
in our investigation, there is no significant 
difference between the amount of the drug 
released from F56, F98, and F125; however, a 
significant increase in the cell cytotoxicity for 
CapryolTM 90-based NEs could be attributed to 
more cell penetration and drug solubilization in 
the internal phase. 
Transport study
Transport studies were performed by using 
the changes of TEER values as indicators for 
cell membrane and integrity of tight junction in 
monolayers of Caco-2 cells. The TEER value 
of Caco-2 cells cultured on filters after 21 days 
was calculated to be 600 Ω.cm2, indicating 
the development of tight junctions and good 
monolayer integrity. TEER was also measured 
from apical to basolateral side at specific times 
(1, 2, 3, 4, 8, and 24 h) in the presence of RAP-
NEs and methanolic solution. After treatment 
of Caco-2 cell monolayers with NEs, it was 
seen that for all three NEs, TEER decreased to 
around 70-80% of the initial value. The decline 
in TEER value after the addition of NEs to the 
apical side is shown in Figure 8 and the plots 
of apical to basolateral transport of RAP-loaded 
NEs and methanolic solution across Caco-
2 cell monolayer is illustrated in Figure 9. 
Formulations containing CapryolTM 90 (F98 and 
F125) caused more decrease in cell integrity and 
drug transport, in comparison with the oleic acid 
containing formulation (F56).
Results obtained from transport studies 
suggested more RAP transport when the NEs are 
applied, compared with the methanolic solution 
and are in line with the apparent permeability 
calculated for each formulation. It seems that as 
a consequence of loading of RAP (with a high 
molecular weight and lipophilic character) in 
NEs, the cell permeability increased (Table 5).
In our previous study, we demonstrated that 
Tween 20, as a surfactant, can cause a significant 
decrease in cell integrity (33). TEER reduction 
represents the opening of tight junctions and 
reduction of cell integrity (36, 56). As reported 
in the literature, the components of these 
systems could contribute to the enhancement of 
drug permeation from nano- or microemulsions 
across monolayer of Caco-2 cells by opening the 
tight junctions temporarily and facilitating drug 
transport through paracellular pathway. Doh and 
co-workers developed a new lipid NE system 
containing granisetron and evaluated its in-vitro Page 25 of 34 
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Figure 8. TEER values of Caco-2 monolayer, after the addition of RAP-loaded nanoemulsions and 
methanolic solution over a period of 24 h (n = 3). 
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Figure 9. Comparison of apical to basolateral transport of RAP-loaded nanoemulsions and methanolic 
solution across Caco-2 cell monolayer (n = 3). 
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permeation-enhancing effect, using Caco-2 cell 
monolayers (57). Their results from permeation 
tests in monolayers of Caco-2 cells revealed that 
the NEs considerably improved the permeation 
of drug compared to the drug powder. They 
suggested that the increase in permeability was 
probably due to the presence of lipoid E-80 
as the surfactant with a profound permeation 
enhancing effect (57, 58). Yin et al. have 
prepared a microemulsion system of docetaxel 
(a substrate of P-gp) and evaluated its oral 
bioavailability improvement (59). In CapryolTM 
90/Cremophor® EL/Transcutol® P system, 
transportation of docetaxel through the Caco-2 
cell monolayer (apical to basolateral direction) 
and the oral bioavailability were significantly 
improved, compared to the commercial product. 
Thus, they concluded that in-vitro absorption 
of docetaxel from microemulsions could be 
significantly enhanced by the surfactants (i.e., 
Cremophor® EL), due to the combined effect 
of P-gp efflux system inhibition and increased 
permeability (59). Permeability enhancement 
effect of polysorbates on human Caco-2 cell 
monolayer has also been studied with Lucifer 
yellow assay and measurements of TEER. It 
has been shown that polysorbates, especially 
polysorbate 20 (Tween 20), could alter TEER 
values and increase Lucifer yellow permeability 
significantly (60). In addition to Cremophor® 
EL, the enhanced permeation probably results 
from other compounds of microemulsions. The 
transportation values (Papp) of many poorly 
lipophilic compounds have been reported to 
be greatly developed by Transcutol® P and its 
improvement of permeation through Caco-2 
cell monolayer was considerably greater than 
PG with the same amount (59, 61). Moreover, 
Cremophor® RH 40 could similarly inhibit P-gp 
efflux pumps (62-64), although it was reported 
that Cremophor® EL inhibits P-gp efflux pumps 
stronger than Cremophor® RH 40 (65). In 
addition to the above mentioned mechanism, 
the properties of NEs, such as the presence of 
nanosized droplets and the interaction between 
the cellular membrane and surfactants, could 
also enhance the drug permeation (57).
Cellular uptake of nanoemulsions
In order to detect the intracellular position 
of coumarin-6, as a hydrophobic cellular uptake 
indicator which could emit green fluorescence 
in SKBR-3 cells, fluorescence microscopy 
was performed using coumarin 6-loaded 
NEs (Figure 10). Fluorescence intensity in 
different cytoplasmic regions with F56, F98, 
F125 formulations, and coumarin methanolic 
solution was 57.18, 59.02, 48.1, and 29.87, 
respectively. The dye was associated with the 
oily part of nanoemulsions and its presence 
Figure 9. Comparison of apical to basolateral transport of RAP-loaded nanoemulsions and methanolic solution across Caco-2 cell 
monolayer (n = 3).
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inside the cells could be expected to be due to 
the internalization of the nanoemulsion droplets 
inside the cells which in turn rendered the cells 
fluorescent. These results are in agreement with 
those obtained from TEER and cytotoxicity 
experiments.
Conclusion
In summary, the results of the present 
investigation demonstrated that the developed 
oil-in-water NEs, composed of oleic acid and 
CapryolTM 90 as inner oil phases, Tween 20 
and Cremophor® RH 40 as surfactants, were 
thermodynamically stable and possessed 
efficient solubilizing capacity for RAP. The 
optimized formulations showed considerable 
toxic activity against breast cancer cell line 
SKBR-3. In-vitro transport studies through 
monolayer of Caco-2 cell also revealed 
considerable enhancement of the drug transport. 
This and the previous investigation showed that 
the use of a nanoemulsion-based vehicle could be 
considered as an effective and promising strategy 
for the delivery of RAP from pharmaceutical and 
toxicological points of view, although further 
studies are required.
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Cellular uptake of nanoemulsions 
In order to detect the intracellular position of coumarin-6, as a hydrophobic cellular uptake indicator which 
could emit green fluorescence in SKBR-3 cells, fluorescence microscopy was performed using coumarin 6-
loaded NEs (Figure 10). Fluorescence intensity in different cytoplasmic regions with F56, F98, F125 
formulations, and coumarin methanolic solution was 57.18, 59.02, 48.1, and 29.87, respectively. The dye 
was associated with the oily part of nanoemulsions and its presence inside the cells could be expected to be 
due to the internalization of the nanoemulsion droplets inside the cells which in turn rendered the cells 
fluorescent. These results are in agreement with those obtained from TEER and cytotoxicity experiments.  
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Figure 10. Fluorescent images of SKBR-3 cells incubated for 6 h with methanolic solution of coumarin. A) 
control; B) Formulation F125; C) Formulation F56; and D) Formulation F98. 
 
Conclusion 
In summary, the results of the present investigation demonstrated that the developed oil-in-water NEs, 
composed of oleic acid and CapryolTM 90 as inner oil phases, Tween 20 and Cremophor RH 40 as 
Figure 10. Fluorescent images of SKBR-3 cells incubated for 6 h with methanolic solution of coumarin. (A) control; (B) Formulation 
F125; (C) Formulation F56; and (D) Formulation F98.
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